Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer
MacroGenics
MacroGenics
Stanford University
Pfizer
Nektar Therapeutics
Eli Lilly and Company
Masonic Cancer Center, University of Minnesota
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
EMD Serono
Copenhagen University Hospital at Herlev
AstraZeneca
Bristol-Myers Squibb